Withdrawal of nifedipine capsules: Jeopardising the treatment of acute severe hypertension in pregnancy?

被引：18

作者：

Brown, MA

McCowan, LME

North, RA

Walters, BN

机构：

[1] ST GEORGE HOSP, DEPT RENAL MED, KOGARAH, NSW 2217, AUSTRALIA

[2] ST GEORGE HOSP, DEPT OBSTET, KOGARAH, NSW 2217, AUSTRALIA

[3] UNIV AUCKLAND, SCH MED, NATL WOMENS HOSP, DEPT OBSTET & GYNAECOL, AUCKLAND, NEW ZEALAND

[4] KING EDWARD MEM HOSP WOMEN, PERTH, WA, AUSTRALIA

[5] COUNCIL AUSTRALASIAN SOC STUDY HYPERTENS PREGNANC, SYDNEY, NSW 2000, AUSTRALIA

来源：

MEDICAL JOURNAL OF AUSTRALIA | 1997年 / 166卷 / 12期

关键词：

D O I：

10.5694/j.1326-5377.1997.tb123300.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Short-acting oral nifedipine has been withdrawn from the Australian market because of reports of ifs adverse effects after long-term treatment in non-pregnant patients with heart disease. This will have a major impact on the treatment of acutely hypertensive pregnant women, in whom the drug has proven to be safe, effective and easy to administer Should pregnant women be forced to use less suitable agents, thus threatening their own and their babies' health?.

引用

页码：640 / 643

页数：4

共 48 条

[11]

FENAKEL K, 1991, OBSTET GYNECOL, V77, P331

[12] A COMPARISON OF TOCOLYSIS WITH NIFEDIPINE OR RITODRINE - ANALYSIS OF EFFICACY AND MATERNAL, FETAL, AND NEONATAL OUTCOME [J].